Success Metrics

Clinical Success Rate
55.6%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
0(0%)
Results Posted
160%(8 trials)
Terminated
4(40%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_1
5
50%
Ph phase_2
3
30%

Phase Distribution

5

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(5)
Terminated(5)

Detailed Status

Completed5
Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
55.6%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)

Trials by Status

withdrawn110%
terminated440%
completed550%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT01054625
terminatedphase_1

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

NCT00707655
completedphase_2

Zalutumumab in Non-curable Patients With SCCHN

NCT00542308
terminatedphase_1

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer

NCT00677924
completedphase_1

Zalutumumab in Head and Neck Cancer

NCT00093041
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01054625Phase 1

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Completed
NCT00707655Phase 1

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Terminated
NCT00542308Phase 2

Zalutumumab in Non-curable Patients With SCCHN

Completed
NCT00677924Phase 1

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer

Terminated
NCT00093041Phase 1

Zalutumumab in Head and Neck Cancer

Completed
NCT00496652Phase 3

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Completed
NCT00382031Phase 3

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Completed
NCT00401401Phase 1

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Terminated
NCT00460551Phase 2

Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer

Terminated
NCT01449357Phase 2

Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10